|
|
|
|
|
|
|
|
|
25.03.26 - 04:54
|
Research Team Confirms Safety of Alzheimer′s Drug Lecanemab (Nippon)
|
|
|
Tokyo, March 25 (Jiji Press)--More than 90 pct of patients receiving Lecanemab, an Alzheimer's drug, in hospitals across Japan have been able to continue treatment without strong side effects, a group of researchers in the country said. Lecanemab, developed by Eisai Co. and Biogen Inc. and put on sale in December 2023, removes amyloid beta from the brain to slow the progress of Alzheimer's ......
|
|
|
|
|
20.03.26 - 10:48
|
England to Review Rejection of Alzheimer′s Drugs for NHS (Bloomberg)
|
|
|
England's drug price regulator will reconsider its decision to rule out using Eli Lilly & Co.'s Alzheimer's disease treatment — and another made Eisai Co. and Biogen Inc. — in the state-run National Health Service, following successful appeals by the companies....
|
|
|
19.03.26 - 12:33
|
Biogen to Present New Late-Breaking Litifilimab Phase 2 AMETHYST Data in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting (GlobeNewswire EN)
|
|
|
CAMBRIDGE, Mass., March 19, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced upcoming scientific presentations at the 2026 American Academy of Dermatology (AAD) Annual Meeting, taking place March 27-31. Late-breaking data from Part A (Phase 2) of the AMETHYST Phase 2/3 study will be presented that highlight litifilimab's effect on cutaneous lupus erythematosus (CLE) disease activity. Litifilimab is a potential first in-class, monoclonal antibody (mAb) targeting blood dendritic cell antigen 2 (BDCA2) and was the first investigational therapy to show positive results in CLE, as shown in the Phase 2 LILAC study. Additional presentations at AAD will provide new insights into measures used to assess the severity of CLE disease activity in both clinical trials and clinical practice....
|
|
|
|
|
|
|
|
|
11.03.26 - 13:03
|
Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy (GlobeNewswire EN)
|
|
|
CAMBRIDGE, Mass., March 11, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) presented additional results from the Phase 1b study of salanersen, an investigational novel antisense oligonucleotide (ASO) given once a year for spinal muscular atrophy (SMA), at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference. The study evaluated salanersen in children who had suboptimal clinical status despite prior administration of gene therapy (onasemnogene abeparvovec-xioi). Salanersen was generally well-tolerated. Participants experienced a slowing of neurodegeneration and functional improvement, including achievement of new World Health Organization (WHO) motor milestones, following initiation of salanersen. These new results include a minimum of one year of follow-up for all participants, building on the interim study data presented at Cure SMA 2025. The company also presented the study designs of the Phase 3 salanersen clinical trials....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
